ReViral Drug Discovery for Respiratory Syncytial Virus (RSV)

ReViral is a UK-based biotechnology company with a portfolio of drugs to treat Respiratory Syncytial Virus (RSV) infection. RSV currently represents a major unmet medical need in children, the elderly and the immunocompromised.

Our most advanced programme, RV521, is a highly potent, orally-administered inhibitor of RSV fusion protein, and has successfully completed a Phase 2a proof-of-concept study in adult volunteers.

RV521 best-in-class drug to treat RSV infections
  • RV521 is an oral antiviral with excellent drug-like characteristics
  • The compound is highly potent against multiple clinical strains of RSV
  • Highly potent against RSV in human vounteers 

RSV Medical Need

  • RSV is a major cause of respiratory infection in children, the immune-compromised and the elderly
  • There are no effective treatments or vaccines available against RSV
  • There is an unmet need for a safe and effective treatment with a simple route of administration
Meet the team...
Latest News
ReViral at 11th International Respiratory Syncytial Virus Symposium

ReViral's CEO, Dr Eddy Littler, and Head of Virology, Dr Elaine Thomas, will be presenting "Low rate of resistance to the RSV fusion inhibitor RV521 in human infection" at...

ReViral to present at RespiDART 2018

ReViral's Chief Scientific Officer, Stuart Cockerill, will be presenting at RespiDART 2018 in Miami on 29th November 2018. The afternoon session entitled "Therapeutics...

ReViral at 6th ISIRV AVG Conference

ReViral's Chief Operating Officer, Dr Rachel Harland, will be presenting the poster "Efficacy of the RSV fusion Inhibitor RV521 in human infection" at The 6th ISIRV AVG...

Contact us...